A Prospective Trial of a Variable Compression System for Moderate to Severe Irritable Bowel Syndrome
Part of paid clinical trials in Kissimmee, Florida.
- Sponsor
- PGP Health
- Study ID
- NCT07540312
- Status
- Recruiting
Conditions
- IBS (Irritable Bowel Syndrome)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- Variable Compression System — DEVICEThe VCS is a wearable device that provides compression of the lower abdomen, torso support, and covers the torso in Far Infrared Radiation (FIR).
Study Details
This prospective, interventional trial is intended to determine the safety and effectiveness of the Variable Compression System (VCS) device for Irritable Bowel Syndrome (IBS). This pilot study will enroll 20 subjects who will be required to wear the VCS device for a minimum of 6 hours a day and follow up at 21 days, 8 weeks, and 6 months post-device administration.
Key Dates
- Start date
- May 21, 2025
- Status verified
- Apr 2026
- Primary completion
- May 1, 2026
- Completion
- May 1, 2026
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Pilot VCS CohortWear VCS device for 6+ hours per day
Primary Outcome Measure
Incidence of intolerable treatment-related adverse events (AEs) [ Time Frame: 21 days ]
Central Contacts
- Agim Beshiri, MD+12623448468
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Central Florida Gastro Research | Kissimmee | Florida | 34741 | Muhammad Mohiuddin, MD (PRINCIPAL_INVESTIGATOR) |
| UChicago Medicine AdventHealth Medical Group Gastroenterology at Bolingbrook | Bolingbrook | Illinois | 60440 | Hadi Saddiqui, DO, MPH (PRINCIPAL_INVESTIGATOR) |
| Delta Gastroenterology PC | Southhaven | Mississippi | 38671 | Ulric Duncan, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Kissimmee, FL
Related Studies
- Efficacy of Rifaximin With NAC in IBS-DPHASE2 · Recruiting · Mark Pimentel, MD · Los Angeles, California
- Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With DiarrheaEARLY_PHASE1 · Not Yet Recruiting · Stanford University · Redwood City, California
- Specimen and Data Collection for a Novel Biomarker Combination for the Differential Diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome.Enrolling By Invitation · DiaSorin Inc. · Minneapolis, Minnesota
- A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported BloatingRecruiting · Kiwi Health Inc · Los Angeles, California